XGN EXAGEN INC.
Services-Medical Laboratories · Nasdaq · SEC CIK 1274737 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.7%
TTM net income YoY4.6%
TTM EPS YoY18.3%
Revenue 3-yr CAGR11.9%
Net income 3-yr CAGR—
Margins
Gross margin58.7%
Operating margin-20.1%
Net margin-25.1%
FCF margin-18.0%
EBITDA margin-16.6%
Returns
ROE-113.9%
ROA-30.8%
ROIC (approx.)-167.2%
Asset turnover1.22x
Leverage & solvency
Liabilities / assets75.1%
Debt / equity1.66x
Current ratio3.46x
Interest coverage-2.90x
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.42M | $19.94M | $17.31M | $16.63M | $17.24M | $17.20M | $15.50M | $13.65M |
| Cost of revenue | $7.58M | $7.72M | $7.10M | $7.42M | $7.17M | $6.81M | $6.38M | $5.18M |
| Gross profit | $10.84M | $12.22M | $10.21M | $9.21M | $10.07M | $10.39M | $9.12M | $8.48M |
| R&D expense | $1.82M | $1.43M | $1.55M | $1.76M | $1.73M | $1.48M | $1.28M | $1.66M |
| SG&A expense | $12.83M | $12.51M | $12.07M | $12.42M | $11.45M | $11.54M | $11.20M | $10.20M |
| Operating income | -$4.41M | -$1.72M | -$3.41M | -$4.97M | -$3.10M | -$2.63M | -$3.37M | -$3.38M |
| Interest expense | $1.20M | $1.20M | $1.27M | $1.33M | $1.32M | $1.12M | $545,000 | $563,000 |
| Income tax | -$1,000 | $0 | $36,000 | $13,000 | $1,000 | $37,000 | $0 | $12,000 |
| Net income | -$6.34M | -$3.20M | -$3.97M | -$4.67M | -$7.09M | -$4.44M | -$3.75M | -$3.76M |
| EBITDA | -$3.71M | -$1.12M | -$2.81M | -$4.38M | -$2.50M | -$2.13M | -$2.96M | -$2.98M |
| EPS (basic) | -0.25 | -0.13 | -0.17 | — | -0.31 | -0.21 | -0.20 | — |
| EPS (diluted) | -0.25 | -0.13 | -0.17 | — | -0.31 | -0.21 | -0.20 | — |
| Weighted avg. shares (diluted) | 24.85M | 24.16M | 23.85M | — | 22.94M | 21.09M | 18.56M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $28.09M | $24.59M | $21.51M | $32.22M | $35.85M | $30.23M | $11.39M | $22.24M |
| Receivables | $11.48M | $12.41M | $15.77M | $10.86M | $11.09M | $14.27M | $14.73M | $7.83M |
| Current assets | $45.33M | $42.86M | $43.58M | $48.89M | $52.59M | $50.99M | $32.51M | $36.45M |
| PP&E, net | $6.06M | $6.57M | $6.61M | $6.94M | $7.49M | $4.58M | $5.03M | $5.28M |
| Total assets | $55.35M | $51.94M | $51.96M | $58.02M | $62.82M | $58.76M | $40.29M | $44.69M |
| Current liabilities | $13.10M | $13.46M | $12.56M | $14.16M | $12.89M | $10.29M | $13.99M | $13.51M |
| Short-term debt | $453,000 | $517,000 | $580,000 | $643,000 | $680,000 | $667,000 | $2.54M | $423,000 |
| Long-term debt | $22.36M | $22.32M | $22.29M | $22.26M | $22.26M | $22.31M | $18.41M | $19.82M |
| Total debt | $22.81M | $22.84M | $22.87M | $22.91M | $22.94M | $22.98M | $20.94M | $20.25M |
| Total liabilities | $41.58M | $39.72M | $37.52M | $40.57M | $44.69M | $37.73M | $33.89M | $35.15M |
| Shareholders' equity | $13.78M | $12.22M | $14.43M | $17.45M | $18.14M | $21.03M | $6.40M | $9.54M |
| Net debt | -$5.28M | -$1.75M | $1.36M | -$9.31M | -$12.91M | -$7.26M | $9.55M | -$1.99M |
| Shares outstanding | 25.42M | 24.19M | 24.09M | 22.91M | 22.51M | 22.00M | 17.95M | 17.64M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.58M | $3.99M | -$10.42M | -$3.01M | $2.94M | -$2.88M | -$10.67M | $363,000 |
| Capital expenditure | $196,000 | $543,000 | $228,000 | $44,000 | $275,000 | $209,000 | $113,000 | $146,000 |
| Free cash flow | -$2.77M | $3.44M | -$10.64M | -$3.06M | $2.67M | -$3.09M | -$10.78M | $217,000 |
| Investing cash flow | -$196,000 | -$543,000 | -$228,000 | -$35,000 | -$275,000 | -$209,000 | -$107,000 | -$146,000 |
| Financing cash flow | $6.28M | -$370,000 | -$62,000 | -$384,000 | $2.95M | $21.93M | -$64,000 | -$216,000 |
| Depreciation & amortization | $700,000 | $600,000 | $600,000 | $600,000 | $600,000 | $500,000 | $400,000 | $400,000 |
| Stock-based compensation | $1.24M | $980,000 | $655,000 | $705,000 | $593,000 | $443,000 | $417,000 | $433,000 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.